Veru selects Laxxon’s SPID technology for modified-release enobosarm

NEW YORK - Veru Inc. (NASDAQ:VERU), a late clinical-stage biopharmaceutical company currently trading at $3.59 per share, has selected Laxxon Medical Corp.’s proprietary SPID (Screen Printing Innovation Drug) Technology for a novel modified-release oral formulation of enobosarm, according to a press release statement. According to InvestingPro data, analysts maintain a strong buy rating on the stock with price targets significantly above current levels.

The formulation achieved its target release profile, including reduced maximum plasma concentration, delayed time to maximum plasma concentration, a distinct secondary peak plasma concentration, and similar extent of absorption compared to immediate release enobosarm capsules.

Enobosarm, a selective androgen receptor modulator, is being developed by Veru as a treatment for cardiometabolic and inflammatory diseases. The company is specifically developing it as a drug that makes weight reduction by GLP-1 RA drugs more tissue selective for fat loss while preserving lean mass.

Mitchell Steiner, Chairman, President, and CEO of Veru, said the modified-release formulation "has multiple benefits when treating the intended patient population and represents a significant advance over conventional drug product dosage forms" as the company moves toward Phase 3 clinical trials. Get deeper insights into Veru’s financial health and growth potential with a comprehensive Pro Research Report, available exclusively on InvestingPro.

Helmut Kerschbaumer, CEO of Laxxon Medical, noted that the milestone "underscores the strength of our SPID-Technology in enhancing bioavailability and optimizing drug release profiles."

Laxxon’s SPID-Technology platform enables various pharmaceutical applications including sequential release of active pharmaceutical ingredients, processing of molecules like peptides with permeation enhancers, and multi-compartment tablets.

The collaboration aims to advance the product development of enobosarm with potential commercialization pending regulatory approval.

In other recent news, Veru Inc. announced positive results from its Phase 2b Maintenance Extension clinical trial, revealing that enobosarm 3mg significantly reduced weight regain by 46% compared to placebo after discontinuation of semaglutide. Following these promising results, Veru has chosen the 3mg dose of enobosarm for its upcoming Phase 3 trials. Additionally, the company has selected a novel modified release formulation for enobosarm, which demonstrated a favorable pharmacokinetic profile in a pilot study. In a strategic move, Veru will implement a 1-for-10 reverse stock split to maintain compliance with Nasdaq requirements. The reverse split, effective on August 8, 2025, will consolidate every 10 shares of common stock into one, with no change to the stock’s par value. Shareholders will receive cash payments for any fractional shares resulting from the split. These developments underscore Veru’s ongoing efforts in advancing its weight management drug and maintaining its market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.